Commercial Insight: Inflammatory Bowel Disease - Convenience and compliance drive market success : Market Research Report

Commercial Insight: Inflammatory Bowel Disease - Convenience and compliance drive market success

Published by: Datamonitor

Published: Sep. 8, 2008 - 263 Pages

ABOUT DATAMONITOR HEALTHCARE: About the Immunology & Inflammation pharmaceutical analysis team
CHAPTER 1 EXECUTIVE SUMMARY: Strategic scoping and focus; Datamonitor insight into the disease market; Related reports; Upcoming related reports
CHAPTER 2 MARKET DEFINITION: The inflammatory bowel disease market definition; Biologics; TNF inhibitors; Integrin inhibitor; Intestinal anti-inflammatory drugs (5-aminosalicylates); Immunomodulators; Corticosteroids; ICD-10 codes used to define the inflammatory bowel disease indications; Crohn's disease; Ulcerative colitis; Assumptions and caveats for diagnosis value estimates; Diagnosis value based on retail data only
CHAPTER 3 PATIENT ACQUISITION PROCESS: Introduction; Patient care path; Points of influence in the patient care path; Trigger Point 1: Disease awareness among patients and physicians is critical to increasing diagnosis rates; Trigger Point 2: Tackling patient compliance during maintenance treatment; Trigger Point 3: Physician assessment of disease severity influences treatment choice - using "step-up" or "top-down" strategies; Factors that influence patient flow through the healthcare system; Increased public awareness leading to early presentation to PCP or a specialist; Symptoms of disease can be mild, therefore, patients do not present for treatment; Patients sometimes forget to take medication if they feel symptoms have improved; Self-management limits patient follow-up
CHAPTER 4 MARKET OVERVIEW: Seven major markets; Current market assessment; Impressive historical growth in inflammatory bowel disease sales from 2004 to 2007; Inflammatory bowel disease market volume is increasing, but due to the uptake of biologics, sales growth is outstripping it; Anti-TNFs contributed to half of all sales in the inflammatory bowel disease market in 2007; Spain and France show highest growth in the seven major markets in 2006-07; Future market assessment; Opportunities and threats; Opportunities; Threats; US; Current market assessment; The US was the largest of the seven major markets in 2007; Anti-TNFs held a 55% share of the US inflammatory bowel disease market in 2007; Corticosteroids demonstrated highest CAGR from 2004 to 2007; Abbott's Humira experienced strong US uptake from 2006 to 2007; Rowasa's US sales continue to decrease in light of generic competition; Future market assessment; Opportunities and threats; Opportunities; Threats; Japan; Current market assessment; Japan was the second largest market in terms of sales in 2007; Intestinal anti-inflammatory drug class dominates inflammatory bowel disease market in Japan; Nisshin Kyorin's Pentasa is the leading brand for inflammatory bowel disease in Japan; Mitsubishi Tanabe's Remicade experiences low growth from 2006 to 2007; Future market assessment; Opportunities and threats; Opportunities; Threats; Europe; Current market assessment; Inflammatory bowel disease sales grew by 28% in the 5EU from 2006 to 2007; Anti-TNFs drive growth in the 5EU inflammatory bowel disease market; Intestinal anti-inflammatory drug class sales remain ahead of anti-TNFs in 5EU; Remicade demonstrated the best performance in the 5EU from 2006 to 2007; Future market assessment; Opportunities and threats; Opportunities; Threats; France; Current market assessment; Inflammatory bowel disease market achieved sales of $137m in 2007; Future market assessment; Germany; Current market assessment; Germany is the largest inflammatory bowel disease market in the 5EU; Future market assessment; Italy; Current market assessment; Second smallest inflammatory bowel disease market behind Spain in 2007; Future market assessment; Spain; Current market assessment; Spain showed highest CAGR of all the major markets from 2004 to 2007; Future market assessment; UK; Current market assessment; Although anti-TNF class is growing rapidly, intestinal anti-inflammatory agents retain largest share of the UK market; Future market assessment; Rest of World snapshot; Current market assessment; Rest of World accounts for only 13% of global inflammatory bowel disease market sales; Global inflammatory bowel disease market sales increased with a 14.3% CAGR from 2004 to 2007; Asia-Pacific, particularly China, is the area of highest growth in the Rest of World; Other regions, such as Russia, show promising growth in the inflammatory bowel disease market; Canada is the largest Rest of World market after the rest of Europe.; Remicade is the leading brand in the Rest of World; Opportunities and threats; Opportunities; Threats
CHAPTER 5 BRAND DYNAMICS: Overview of competitive landscape; Drivers of brand choice; Factors driving brand choice in the anti-TNF class; Patient preference, cost and mode of delivery are among drivers of brand choice for anti-TNFs; US formulary status for leading brands; Humira is better positioned than Remicade in most US formularies; Asacol has desirable Tier-2 coverage in most plans; Remicade (infliximab; Centocor/Johnson & Johnson, Schering-Plough and Mitsubishi Tanabe); Drug profile; Product positioning; Remicade is positioned in multiple Crohn's disease patient populations; Ulcerative colitis approval expands scope for Remicade product positioning; Colectomy avoidance indication will have a small positive impact on Remicade sales; Remicade advances up to second-line therapy for Crohn's disease in the EU; SONIC trial directly evaluates Remicade against immunosuppressants; Marketing mix; Marketing mix for Remicade is varied, but Centocor is promoting the message of evidence and experience; Centocor finds new marketing channel in the form of a documentary; Mitsubishi Tanabe's strengthened promotion of Remicade in Japan is a core marketing strategy; Brand forecast to 2017; Remicade's sales grow in the near term but then decline amid competition from new products and biosimilars; Japan is the only major market where Remicade will experience overall growth to 2017; Infliximab biosimilars will achieve sales of $160m in 2017; Strategic recommendations; Humira (adalimumab; Abbott, Eisai); Drug profile; Product positioning; The GAIN trial positioned Humira to capture infliximab-failure patients, however, competition now comes from Cimzia and Tysabri; Abbott now has 2-year data for Humira, which will allow better positioning against Remicade; Humira is building up clinical data beyond remission; Remicade will remain choice ahead of Humira for treating fistulizing Crohn's disease; Marketing mix; Abbott has relied on heavy marketing of Humira; Abbott signs up Eisai to co-promote Humira in Japan; Abbott promoted the "sustainable impact" of Humira at the DDW 2008; Brand forecast to 2017; Humira will experience strong uptake for inflammatory bowel disease in the seven major markets and will be market leader by 2014; Strategic recommendations; Cimzia (certolizumab; UCB); Drug profile; Product positioning; UCB chose a lower price point to position Cimzia in the competitive anti-TNF market; Like Humira, Cimzia will be positioned in the infliximab-failure population, but as third-line choice; Marketing mix; UCB must launch a hard-hitting marketing campaign for Cimzia; 'CIMplicity' includes the home health nurse program for Cimzia administration; Crohn's & Me society will increase disease awareness and promote Cimzia; UCB and Otsuka will co-promote Cimzia in Japan; Brand forecast to 2017; Third-line competition will cap Cimzia sales in inflammatory bowel disease; Strategic recommendations; Tysabri (natalizumab; Biogen Idec, Elan); Drug profile; Product positioning; Tysabri positioned towards Crohn's disease patients who fail anti-TNF therapy; Tysabri reduces hospitalization rates; Elan and Biogen Idec funded study shows Tysabri most cost-effective therapy for anti-TNF-failure patients; Marketing mix; TOUCH program - newly confirmed cases of PML will limit uptake of Tysabri in Crohn's disease; Brand forecast to 2017; Safety concerns dampen Tysabri's sales forecast in Crohn's disease; Strategic recommendations; Asacol (mesalazine, Procter & Gamble); Drug profile; Product positioning; Procter & Gamble's strong product positioning facilitates Asacol's market leadership; Asacol looking to compete with Pentasa in Japan; Marketing mix; Asacol is the most heavily promoted intestinal anti-inflammatory brand, but Lialda is close behind; Brand forecast to 2017; Competition from Lialda and Salofalk Granustix will diminish Asacol's US and 5EU sales; Strategic recommendations; Pentasa (mesalazine; Shire, Ferring, Nisshin Kyorin); Drug profile; Product positioning; Pentasa has ulcerative colitis indication, but Crohn's disease generates majority of sales, especially in the US; Pentasa and Lialda co-exist in Shire's gastroenterology franchise without signs of cannibalization; Once-daily Pentasa more effective than twice-daily dosing of Pentasa; Marketing mix; Pentasa's promotional spend falls behind Asacol and Lialda; Brand forecast to 2017; Strategic recommendations; Lialda/Mezavant (MMX mesalazine; Shire, Giuliani, Cosmo); Target product profile; Product positioning; Shire will roll-out Lialda across the rest of the EU in 2008; Shire markets Lialda as a once-daily tablet in the US, but reduced number of tablets per day does not equate to lower costs; Lialda aims to acquire share from market-leader Asacol; Marketing mix; Shire and Takeda will co-promote Lialda in the US; Drug forecast to 2017; Once-daily dosing and reduced pill burden will propel Lialda to become the market-leading 5-ASA brand; Strategic recommendations; Golimumab (CNTO-148; Centocor/Johnson & Johnson, Schering-Plough, Mitsubishi Tanabe, Janssen Pharmaceutical); Target product profile; Development overview; Product positioning; Centocor/Johnson & Johnson and Schering-Plough will position golimumab (CNTO-148) in the ulcerative colitis population; Marketing mix; Golimumab's (CNTO-148) marketing will be akin to Remicade's; Drug forecast to 2017; Strategic recommendations; Other marketed brands; Salofalk Granustix (mesalazine; Dr Falk Pharma, Salix Pharmaceuticals); Salofalk Granustix is a once-daily granule mesalazine formulation and will compete with Lialda in the US; Salix Pharmaceuticals's experienced sales force an advantage to Salofalk Granustix; Entocort (budesonide; Prometheus Laboratories, AstraZeneca)

Abstract

Introduction

Several product launches and indication expansion caused substantial sales growth in the seven major inflammatory bowel disease markets from $1.7 billion in 2004 to $2.7 billion in 2007. Datamonitor forecasts the IBD market will grow with a CAGR (200717) of 4.6% to reach $4 billion in 2017 and success will depend on brands demonstrating patient convenience and improved compliance. Scope

In-depth analysis of the current and future inflammatory bowel disease market across the US, 5 EU and Japanese markets, and a rest of world snapshot
Crohn's disease and ulcerative colitis specific sales forecasts for key brands to 2017, with total brand figures to benchmark IBD sales against
Provides detailed brand dynamics discussion, including analysis of the anti-TNFs Remicade, Humira, Cimzia and impact of new products such as Tysabri
Assess the strategies of the key developers in the IBD market

Highlights

Anti-TNF sales will peak at over $2 billion in 2012 because of earlier use, extension into ulcerative colitis, uptake of Cimzia (certolizumab) and the launch of golimumab (CNTO-148). Despite competitive pressure from novel agents and biosimilars, the TNF inhibitors will generate $1.8 billion in IBD indications in 2017 and retain market dominance.
Cimzia is the third anti-TNF for Crohn's disease, but with few perceived advantages, it will remain a third-line therapy. Time on the market, method of delivery and patient preference will increasingly determine anti-TNF choice. Humira will attain market and class leadership from Remicade by 2014, achieving IBD sales of $0.8 billion by 2017.
Patient convenience/compliance will drive brand choice in the homogenous 5-ASA class. Lialda reduces pill burden and data indicate superiority to Asacol. With its favorable once-daily dosing, Lialda is set to head the 5-ASA class and smart marketing will minimize Pentasa cannibalization. Lialda will generate total brand sales of over $400 m in 2017

Reasons to Purchase

Quantify the current size of IBD sales in the seven major markets and understand trends in the rest of the world
Assess the impact of events, such as biosimilars entry, on sales of over 30 key brand name products
Understand the IBD patient acquisition process as well as specific market opportunities and threats

Please Note: This product is delivered as a zip file

Get Full Details About This Report >>

US: 800.298.5699

Int'l: +1.240.747.3093

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 160,000 market research reports, company profiles and country profiles from over 600 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.

Commercial Insight: Inflammatory Bowel Disease - Convenience and compliance drive market success

Table of Contents

Abstract